Abstract
Elimination of solid tumors refractory to the standard approaches is a significant challenge. The hypothesis that cancer stem cells (CSC) are responsible for the resistance to treatment, require novel therapies for cancer. Although recent studies determined phenotypes associated with CSC in distinct tumors, therapeutics lags behind. It is possible that the originally described CSC contain cells in different stages of differentiation and in different phases of the cell cycle. Most CSC should be sensitive to current treatment with enzyme inhibitors (PI3K, HDAC, PARP). In some patients, tumors recur after long periods (20-24 months) of disease free life. Novel molecular therapies, with inhibitory RNA or metastasespreventive vaccine are needed for patients which develop metastases originating from small numbers of cancer cells undetectable at the time of cure. We hypothesize that a common denominator of molecular therapies against CSC is the need for two agents: one, (available) which inhibits cell-cycle progression and a second, (to be developed) which kills “resting“ CSC.
Current Cancer Therapy Reviews
Title: Working Hypothesis: Elimination of Cancer Stem Cells in Solid Tumors by Immuno-Gene Therapy Using Cancer Vaccines and Created-Inhibitory RNA
Volume: 5 Issue: 3
Author(s): Takashi Mine, Soldano Ferrone, Georges Vlastos, George E. Peoples and Constantin G. Ioannides
Affiliation:
Abstract: Elimination of solid tumors refractory to the standard approaches is a significant challenge. The hypothesis that cancer stem cells (CSC) are responsible for the resistance to treatment, require novel therapies for cancer. Although recent studies determined phenotypes associated with CSC in distinct tumors, therapeutics lags behind. It is possible that the originally described CSC contain cells in different stages of differentiation and in different phases of the cell cycle. Most CSC should be sensitive to current treatment with enzyme inhibitors (PI3K, HDAC, PARP). In some patients, tumors recur after long periods (20-24 months) of disease free life. Novel molecular therapies, with inhibitory RNA or metastasespreventive vaccine are needed for patients which develop metastases originating from small numbers of cancer cells undetectable at the time of cure. We hypothesize that a common denominator of molecular therapies against CSC is the need for two agents: one, (available) which inhibits cell-cycle progression and a second, (to be developed) which kills “resting“ CSC.
Export Options
About this article
Cite this article as:
Mine Takashi, Ferrone Soldano, Vlastos Georges, Peoples E. George and Ioannides G. Constantin, Working Hypothesis: Elimination of Cancer Stem Cells in Solid Tumors by Immuno-Gene Therapy Using Cancer Vaccines and Created-Inhibitory RNA, Current Cancer Therapy Reviews 2009; 5 (3) . https://dx.doi.org/10.2174/157339409788982250
DOI https://dx.doi.org/10.2174/157339409788982250 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Boronated Compounds for Imaging Guided BNCT Applications
Anti-Cancer Agents in Medicinal Chemistry Discovering Natural Product Modulators to Overcome Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Biotechnology Possible Binding Mode Analysis of Pyrazolo-triazole Hybrids as Potential Anticancer Agents through Validated Molecular Docking and 3D-QSAR Modeling Approaches
Letters in Drug Design & Discovery Current Dendrimer Applications in Cancer Diagnosis and Therapy
Current Topics in Medicinal Chemistry Telomere Recombination and the ALT Pathway: A Therapeutic Perspective for Cancer
Current Pharmaceutical Design Identification and Targeting of Tumor Escape Mechanisms: A New Hope for Cancer Therapy?
Current Pharmaceutical Design Translocator Protein as a Promising Target for Novel Anxiolytics
Current Topics in Medicinal Chemistry DLX6-AS1: An Indispensable Cancer-related Long Non-coding RNA
Current Pharmaceutical Design Theranostic Radiopharmaceuticals Based on Gold Nanoparticles Labeled with <sup>177</sup>Lu and Conjugated to Peptides
Current Radiopharmaceuticals Quercetin in Cancer Treatment, Alone or in Combination with Conventional Therapeutics?
Current Medicinal Chemistry Recent Advances in Understanding and Exploiting the Activation of Anthracyclines by Formaldehyde
Current Medicinal Chemistry - Anti-Cancer Agents Abnormal Choline Phospholipid Metabolism in Breast and Ovary Cancer:Molecular Bases for Noninvasive Imaging Approaches
Current Medical Imaging Editorial (Thematic Issue: Engineered Magnetic Core@Shell Structures)
Current Pharmaceutical Design Epigenetic MicroRNA Regulation of Multiple Chromatin Functions: A Perspective in Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Recent Progress in Biomedical Applications of Magnetic Nanoparticles
Recent Patents on Nanotechnology Delivery of Nanoparticles for Treatment of Brain Tumor
Current Drug Metabolism Transductional and Transcriptional Targeting of Adenovirus for Clinical Applications
Current Gene Therapy Current Non-viral Gene Therapy Strategies for the Treatment of Glioblastoma
Current Medicinal Chemistry Gender Differences in the Antioxidant Response to Oxidative Stress in Experimental Brain Tumors
Current Cancer Drug Targets P-Glycoprotein Mediated Multidrug Resistance Reversal by Phytochemicals: A Review of SAR & Future Perspective for Drug Design
Current Topics in Medicinal Chemistry